File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis by Natural Products: Is It the Dawning of a New Era?

TitleTargeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis by Natural Products: Is It the Dawning of a New Era?
Authors
Keywordsapoptosis
cell activation
cell aging
Chinese medicine
drug efficacy
Issue Date2020
PublisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/pharmacology
Citation
Frontiers in Pharmacology, 2020, v. 11, p. article no. 548 How to Cite?
AbstractLiver fibrosis is a progressive liver damage condition that is worth studying widely. It is important to target and alleviate the disease at an early stage before turning into later cirrhosis or liver cancer. There are currently no direct medicines targeting the attenuation or reversal of liver fibrosis, and so there is an urgent need to look into this area. Traditional Chinese Medicine has a long history in using herbal medicines to treat liver diseases including fibrosis. It is time to integrate the ancient wisdom with modern science and technology to look for the best solution to the disease. In this review, the principal concept of the pathology of liver fibrosis will be described, and then some of the single compounds isolated from herbal medicines, including salvianolic acids, oxymatrine, curcumin, tetrandrine, etc. will be discussed from their effects to the molecular mechanism behind. Molecular targets of the compounds are analyzed by network pharmacology approach, and TGFβ/SMAD was identified as the most common pathway. This review serves to summarize the current findings of herbal medicines combining with modern medicines in the area of fibrosis. It hopefully provides insights in further pharmaceutical research directions.
Persistent Identifierhttp://hdl.handle.net/10722/284279
ISSN
2020 Impact Factor: 5.81
2015 SCImago Journal Rankings: 1.845
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, YT-
dc.contributor.authorWang, N-
dc.contributor.authorTan, HY-
dc.contributor.authorLi, S-
dc.contributor.authorFeng, Y-
dc.date.accessioned2020-07-20T05:57:28Z-
dc.date.available2020-07-20T05:57:28Z-
dc.date.issued2020-
dc.identifier.citationFrontiers in Pharmacology, 2020, v. 11, p. article no. 548-
dc.identifier.issn1663-9812-
dc.identifier.urihttp://hdl.handle.net/10722/284279-
dc.description.abstractLiver fibrosis is a progressive liver damage condition that is worth studying widely. It is important to target and alleviate the disease at an early stage before turning into later cirrhosis or liver cancer. There are currently no direct medicines targeting the attenuation or reversal of liver fibrosis, and so there is an urgent need to look into this area. Traditional Chinese Medicine has a long history in using herbal medicines to treat liver diseases including fibrosis. It is time to integrate the ancient wisdom with modern science and technology to look for the best solution to the disease. In this review, the principal concept of the pathology of liver fibrosis will be described, and then some of the single compounds isolated from herbal medicines, including salvianolic acids, oxymatrine, curcumin, tetrandrine, etc. will be discussed from their effects to the molecular mechanism behind. Molecular targets of the compounds are analyzed by network pharmacology approach, and TGFβ/SMAD was identified as the most common pathway. This review serves to summarize the current findings of herbal medicines combining with modern medicines in the area of fibrosis. It hopefully provides insights in further pharmaceutical research directions.-
dc.languageeng-
dc.publisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/pharmacology-
dc.relation.ispartofFrontiers in Pharmacology-
dc.rightsThis Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectapoptosis-
dc.subjectcell activation-
dc.subjectcell aging-
dc.subjectChinese medicine-
dc.subjectdrug efficacy-
dc.titleTargeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis by Natural Products: Is It the Dawning of a New Era?-
dc.typeArticle-
dc.identifier.emailChan, YT: ecyt1@hku.hk-
dc.identifier.emailWang, N: ckwang@hku.hk-
dc.identifier.emailTan, HY: hyhtan@hku.hk-
dc.identifier.emailLi, S: lishaha@hku.hk-
dc.identifier.emailFeng, Y: yfeng@hku.hk-
dc.identifier.authorityWang, N=rp02075-
dc.identifier.authorityFeng, Y=rp00466-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3389/fphar.2020.00548-
dc.identifier.pmid32425789-
dc.identifier.pmcidPMC7212390-
dc.identifier.scopuseid_2-s2.0-85084760490-
dc.identifier.hkuros311482-
dc.identifier.volume11-
dc.identifier.spagearticle no. 548-
dc.identifier.epagearticle no. 548-
dc.identifier.isiWOS:000536107300001-
dc.publisher.placeSwitzerland-
dc.identifier.issnl1663-9812-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats